At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 336 enrolled
Drug / intervention
Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)drug
Likely dose
Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321) 2 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-label, Randomized, Active-controlled, Parallel-group, Phase-3b Study of the Efficacy, Safety, and Tolerability of 2 mg Aflibercept Administered by Intravitreal Injections Using Two Different Treatment Regimens to Subjects With Neovascular Age-related Macular Degeneration (nAMD).
In Brief
A Phase 3 clinical trial evaluating Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321) for Macular Degeneration. Completed, enrolled 336 participants across 71 sites in 14 countries.
Detailed Summary
To compare the efficacy of 2 mg aflibercept administered by two different intravitreal (IVT) treatment regimens to subjects with neovascular age-related macular degeneration (nAMD)
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMacular Degeneration
CountriesAustria, Canada, Czechia, France, Germany, Hungary, Italy, Lithuania, Poland, Portugal, Slovakia, Spain, Switzerland, United Kingdom
Collaborators--
Timeline
Phase 3CompletedFinished
20162017201820192020202120222023202420252026
First PostedSep 2015
Enrollment StartSep 2015
Primary CompletionDec 2019
Study CompletionJun 2020
TodayJul 2026
First PostedSep 4, 2015
Enrollment StartSep 29, 2015
Primary CompletionDec 24, 2019
Study CompletionJun 4, 2020
TodayJul 2, 2026
Enrollment to primary: 4.2 yearsPosted 10.8 years ago
Interventions
Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)drug
A dose of 2 mg aflibercept injected intravitreally